Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03911973 · ClinicalTrials.gov registry record · Phase 1
Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers
A Phase 1 study of TNBC - Triple-Negative Breast Cancer, sponsored by Kari Wisinski.
- Active
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
- 5
- Study locations
NCT03911973 is a Phase 1 study of TNBC - Triple-Negative Breast Cancer that is active but no longer recruiting, run by Kari Wisinski. The registered enrollment target is 37 participants, below the 480-participant average among 22 other TNBC - Triple-Negative Breast Cancer trials with a reported enrollment target (92% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT03911973, a Phase 1 study of TNBC - Triple-Negative Breast Cancer, is active but no longer recruiting, sponsored by Kari Wisinski.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is designed to determine the RP2D of gedatolisib in combination with talazoparib and to evaluate the efficacy of this combination in advanced HER2 negative breast cancer that is triple negative or BRCA1/2 positive (deficient).
Conditions Studied
Interventions
- DRUG Talazoparib
- DRUG Gedatolisib
Study Locations (5)
Illinois
- Northwestern University Feinberg School of Medicine - Chicago
- University of Illinois Cancer Center - Chicago
Indiana
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center - Indianapolis
Iowa
- University of Iowa Hospital and Clinics - Iowa City
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2019-04-17 |
| Est. Completion | 2024-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03911973
The ClinicalTrials.gov registry entry for NCT03911973 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 480-participant average among 22 other TNBC - Triple-Negative Breast Cancer trials with a reported enrollment target (92% lower). The listed sponsor is Kari Wisinski, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with TNBC - Triple-Negative Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Talazoparib is the first listed.
NCT03911973 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Illinois, Indiana, Iowa.
Frequently Asked Questions
What is clinical trial NCT03911973 about?
NCT03911973 is a clinical study titled "Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers". This study is designed to determine the RP2D of gedatolisib in combination with talazoparib and to evaluate the efficacy of this combination in advanced HER2 negative breast cancer that is triple negative or BRCA1/2 positive (deficient).
What is the current status of trial NCT03911973?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2019-04-17. Estimated completion is 2024-07.
What conditions does trial NCT03911973 study?
This clinical trial studies the following conditions: TNBC - Triple-Negative Breast Cancer.
What interventions are being tested in trial NCT03911973?
The interventions under investigation include: Talazoparib (DRUG), Gedatolisib (DRUG).
Who is sponsoring clinical trial NCT03911973?
This trial is sponsored by Kari Wisinski, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03911973 being conducted?
This trial has 5 study locations across Illinois, Indiana, Iowa, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for TNBC - Triple-Negative Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
RECRUITING · Phase 1
-
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Study of LP-184 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.